Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-06-18
DOI
https://doi.org/10.3324/haematol.2026.300836
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma

Yufeng Liang, Weizhe Wu, Jie Yang, H Jiang et al.
Haematologica
Lymphoma Diagnosis and Treatment
article

Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma

Yufeng Liang, Weizhe Wu, Jie Yang, H Jiang, Siqi Dong, Ziyan Luo, Haiying Huang, Meng Wang, Lin Qiu
article en

Abstract

No abstract available for this paper.
Haematologica
Guangzhou Women and Children Medical Center (CN), Guangzhou Medical University (CN)
Zero hunger
Openalex Percentile: Top 6%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.